Zymeworks to Host Third Quarter Results Conference Call
October 18 2022 - 8:30AM
Business Wire
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical
company developing multifunctional biotherapeutics, today announced
that management will report its third quarter 2022 financial
results after market close on November 8th, 2022. Following the
announcement, management will host a conference call and webcast to
discuss financial results and provide a corporate update on
November 8th, 2022 at 4:30 p.m. ET.
Conference Call and Webcast Information
The event will be webcast live with dial-in details and webcast
replays available on Zymeworks’ website at
http://ir.zymeworks.com/events-and-presentations.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company
dedicated to the discovery, development and commercialization of
next-generation multifunctional biotherapeutics. Zymeworks’ suite
of therapeutic platforms and its fully integrated drug development
engine enable precise engineering of highly differentiated product
candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a
novel Azymetric™ HER2-targeted bispecific antibody currently being
evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials
globally as a targeted treatment option for patients with solid
tumors that express HER2. Zymeworks’ second clinical candidate,
ZW49, is a novel bispecific HER2 ‑targeted antibody-drug conjugate
currently in Phase 1 clinical development and combines the unique
design and antibody framework of zanidatamab with Zymeworks’
proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also
advancing a deep preclinical pipeline in oncology (including
immuno-oncology agents) and other therapeutic areas. In addition,
its therapeutic platforms are being leveraged through strategic
partnerships with global biopharmaceutical companies. For more
information on our ongoing clinical trials visit
www.zymeworksclinicaltrials.com. For additional information about
Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on
Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221018005422/en/
Jack Spinks (604) 678-1388 ir@zymeworks.com Media Inquiries:
Diana Papove (604) 678-1388 media@zymeworks.com
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Jul 2023 to Jul 2024